Public assistance in patients with acute heart failure: a report from the KCHF registry.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
06 2022
Historique:
revised: 11 02 2022
received: 30 09 2021
accepted: 03 03 2022
pubmed: 16 3 2022
medline: 6 5 2022
entrez: 15 3 2022
Statut: ppublish

Résumé

There is a scarcity of data on the post-discharge prognosis in acute heart failure (AHF) patients with a low-income but receiving public assistance. The study sought to evaluate the differences in the clinical characteristics and outcomes between AHF patients receiving public assistance and those not receiving public assistance. The Kyoto Congestive Heart Failure registry was a physician-initiated, prospective, observational, multicentre cohort study enrolling 4056 consecutive patients who were hospitalized due to AHF for the first time between October 2014 and March 2016. The present study population consisted of 3728 patients who were discharged alive from the index AHF hospitalization. We divided the patients into two groups, those receiving public assistance and those not receiving public assistance. After assessing the proportional hazard assumption of public assistance as a variable, we constructed multivariable Cox proportional hazard models to estimate the risk of the public assistance group relative to the no public assistance group. There were 218 patients (5.8%) receiving public assistance and 3510 (94%) not receiving public assistance. Patients in the public assistance group were younger, more frequently had chronic coronary artery disease, previous heart failure hospitalizations, current smoking, poor medical adherence, living alone, no occupation, and a lower left ventricular ejection fraction than those in the no public assistance group. During a median follow-up of 470 days, the cumulative 1 year incidences of all-cause death and heart failure hospitalizations after discharge did not differ between the public assistance group and no public assistance group (13.3% vs. 17.4%, P = 0.10, and 28.3% vs. 23.8%, P = 0.25, respectively). After adjusting for the confounders, the risk of the public assistance group relative to the no public assistance group remained insignificant for all-cause death [hazard ratio (HR), 0.97; 95% confidence interval (CI), 0.69-1.32; P = 0.84]. Even after taking into account the competing risk of all-cause death, the adjusted risk within 180 days in the public assistance group relative to the no public assistance group remained insignificant for heart failure hospitalizations (HR, 0.93; 95% CI, 0.64-1.34; P = 0.69), while the adjusted risk beyond 180 days was significant (HR, 1.56; 95% CI, 1.07-2.29; P = 0.02). The AHF patients receiving public assistance as compared with those not receiving public assistance had no significant excess risk for all-cause death at 1 year after discharge or a heart failure hospitalization within 180 days after discharge, while they did have a significant excess risk for heart failure hospitalizations beyond 180 days after discharge. https://clinicaltrials.gov/ct2/show/NCT02334891 (NCT02334891) and https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017241 (UMIN000015238).

Identifiants

pubmed: 35289117
doi: 10.1002/ehf2.13898
pmc: PMC9065832
doi:

Banques de données

ClinicalTrials.gov
['NCT02334891']
UMIN-CTR
['UMIN000015238']

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1920-1930

Informations de copyright

© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Circ Rep. 2019 Oct 26;1(11):517-524
pubmed: 33693094
ESC Heart Fail. 2017 Aug;4(3):216-223
pubmed: 28772047
JAMA Netw Open. 2020 May 1;3(5):e204296
pubmed: 32379331
J Am Coll Cardiol. 2012 Oct 9;60(15):1438-54
pubmed: 23036636
BMJ Open. 2020 Feb 16;10(2):e032674
pubmed: 32066601
Curr Heart Fail Rep. 2017 Oct;14(5):385-392
pubmed: 28785969
Lancet. 2011 Sep 17;378(9796):1106-15
pubmed: 21885107
Lancet Glob Health. 2020 Mar;8(3):e411-e422
pubmed: 32087174
ESC Heart Fail. 2022 Jun;9(3):1920-1930
pubmed: 35289117
JACC Heart Fail. 2019 Sep;7(9):746-755
pubmed: 31466671
Heart Vessels. 2022 Jan;37(1):83-90
pubmed: 34156517
Am J Cardiol. 2001 Jun 15;87(12):1367-71
pubmed: 11397355
Circ J. 2018 Oct 25;82(11):2811-2819
pubmed: 30259898
JACC Heart Fail. 2020 Nov;8(11):917-927
pubmed: 33039444
JAMA Netw Open. 2019 Jun 5;2(6):e195892
pubmed: 31225889
Heart. 2021 Feb;107(3):208-216
pubmed: 33082175

Auteurs

Yuji Nishimoto (Y)

Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan.

Takao Kato (T)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Takeshi Morimoto (T)

Department of Clinical Epidemiology, Hyogo College of Medicine, Hyogo, Japan.

Ryoji Taniguchi (R)

Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan.

Hidenori Yaku (H)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Yasutaka Inuzuka (Y)

Department of Cardiology, Shiga Medical Center for Adults, Shiga, Japan.

Yodo Tamaki (Y)

Division of Cardiology, Tenri Hospital, Nara, Japan.

Erika Yamamoto (E)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Yusuke Yoshikawa (Y)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Takeshi Kitai (T)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.

Moritake Iguchi (M)

Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.

Masashi Kato (M)

Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan.

Mamoru Takahashi (M)

Department of Cardiology, Shimabara Hospital, Kyoto, Japan.

Toshikazu Jinnai (T)

Department of Cardiology, Japanese Red Cross Otsu Hospital, Shiga, Japan.

Tomoyuki Ikeda (T)

Department of Cardiology, Hikone Municipal Hospital, Shiga, Japan.

Kazuya Nagao (K)

Department of Cardiology, Osaka Red Cross Hospital, Osaka, Japan.

Takafumi Kawai (T)

Department of Cardiology, Kishiwada City Hospital, Osaka, Japan.

Akihiro Komasa (A)

Department of Cardiology, Kansai Electric Power Hospital, Osaka, Japan.
Department of Cardiology, Shizuoka General Hospital, Shizuoka, Japan.

Ryusuke Nishikawa (R)

Department of Cardiology, Kurashiki Central Hospital, Okayama, Japan.

Yuichi Kawase (Y)

Department of Cardiology, Kurashiki Central Hospital, Okayama, Japan.

Takashi Morinaga (T)

Department of Cardiology, Kokura Memorial Hospital, Fukuoka, Japan.

Kanae Su (K)

Department of Cardiology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.

Mitsunori Kawato (M)

Department of Cardiology, Nishi-Kobe Medical Center, Hyogo, Japan.

Yuta Seko (Y)

Cardiovascular Center, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan.

Moriaki Inoko (M)

Cardiovascular Center, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan.

Mamoru Toyofuku (M)

Department of Cardiology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.

Yutaka Furukawa (Y)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.

Yoshihisa Nakagawa (Y)

Division of Cardiology, Tenri Hospital, Nara, Japan.

Kenji Ando (K)

Department of Cardiology, Kokura Memorial Hospital, Fukuoka, Japan.

Kazushige Kadota (K)

Department of Cardiology, Kurashiki Central Hospital, Okayama, Japan.

Satoshi Shizuta (S)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Koh Ono (K)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Koichiro Kuwahara (K)

Department of Cardiovascular Medicine, Shinshu University Graduate School of Medicine, Matsumoto, Japan.

Neiko Ozasa (N)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Yukihito Sato (Y)

Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan.

Takeshi Kimura (T)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH